The Future of Global Health Procurement: Issues around Pricing Transparency

Mikel Berdud;Adrian Towse;Kalipso Chalkidou;Emma Dean;Jimena Ferraro;Lou Garrison;Cassandra Nemzoff

Grant-Funded Research from Office of Health Economics

Abstract: This OHE Research Paper focuses on the role that price transparency may play in the efficient and effective procurement of medicines by Middle and Low Income Countries. Will making prices publicly available make procurement more efficient and cost-effective medicines more accessible? This OHE Research Paper focuses on the role that price transparency may play in the efficient and effective procurement of medicines by Middle and Low Income Countries. Will making prices publicly available make procurement more efficient and cost-effective medicines more accessible? This study was commissioned and funded by The Center for Global Development as research to support its Working Group on the Future of Global Health Procurement. Over the next few years, many Middle Income Countries will increase their GDPs such that they lose their eligibility for aid. Some Low Income Countries will also grow rapidly and lose eligibility. Countries have then to implement strategies to increase the domestic resources allocated for health, manage their resources more effectively, and make wise purchasing decisions, including both off-patent and on-patent medicines. The paper concludes that transparency of the procurement processes significantly lowers costs by encouraging bidders. The authors do not recommend price transparency for on-patent medicines as the effect will be to slow the diffusion of innovative products to low income countries. Differential pricing is important and can best be achieved in the current environment via confidential discounts. Developing country markets are, however, dominated by generic products. Price transparency for off-patent products could improve market efficiency if capacities are there to use the data to inform procurement decisions. whilst protecting against supplier collusion. However, price transparency increases the opportunity for collusion by enabling generic suppliers to observe one another’s prices. Any consideration of price transparency must take this possibility into account. The report recommends consideration of one-sided disclosure of multi-source prices, i.e. buyers should share price data for off-patent medicines amongst themselves.

Keywords: The; Future; of; Global; Health; Procurement:; Issues; around; Pricing; Transparency (search for similar items in EconPapers)
JEL-codes: I1 (search for similar items in EconPapers)
Date: 2019-03-01
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.ohe.org/publications/future-global-hea ... al-28-march-2019-v2/ (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:ohe:grafun:002150

Access Statistics for this paper

More papers in Grant-Funded Research from Office of Health Economics Contact information at EDIRC.
Bibliographic data for series maintained by Publications Manager ( this e-mail address is bad, please contact ).